Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
National Multiple Sclerosis Society
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years and older.
Diagnosis of relapsing-remitting multiple sclerosis (RRMS) based on revised McDonald criteria
At least two Gd-enhancing lesions on the brain or spinal cord MRI done in the prior three months
Naïve to disease modifying therapies or using an injectable therapy (interferons or glatiramer acetate); or, if history of receiving natalizumab, fingolimod, dimethyl fumarate and teriflunomide, no exposure for past three months
Expanded Disability Status Scale (EDSS) score at the time of screening =\<3
You may not be if
Contraindication to treatment with B-cell depleting antibodies, including being seropositive for HBsAg or HIV antibody or T-spot (or Quantiferon-Gold) positive
Ever received B-cell depleting antibodies (rituximab, ocrelizumab, ofatumumab), alemtuzumab, daclizumab, mitoxantrone or hematopoietic stem-cell transplant
Female who are pregnant, nursing or unwilling to use contraception up to six months after the second course of the infusion (or 12 months after the first infusion)
Treatment with steroids in the past 30 days
Clinically unstable medical or psychiatric disorders at the time of screening that require acute treatment as determined by the PI
Clareo Health | Short-term B-cell Depletion in Relapsing Multiple Sclerosis
